|
Figure 9 Compound 8b effectively inhibits angiogenesis in Tg(fli1:EGFP) zebrafish embryos with fluorescently labeled endothelial cells. Embryos were exposed to the four doses of 8b and assessed the inhibition of ISV vasculature at 48 hpf (A). Treatment with 8b increased the number of embryos with the anti-angiogenic phenotype (B), decreased the number of normally developed ISVs (C), and reduced the ISV length (D) in the dose-dependent manner. Sunitinib-malate (Suten), a clinically approved anti-angiogenic drug, was used as a positive control. While the Suten caused life-threating cardiotoxicity at the effective dose of 1.56 µM, 8b inhibited angiogenesis without any toxic response in the treated embryos. Representative images of embryos are shown. Data are normalized in relation to the control group (B,C). Significance in the analyzed parameters between 8b-treated embryos and control (DMSO-treated) embryos is indicated with asterisks (** p < 0.01; *** p < 0.001).